Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets.

Kwak JE, Kim YI, Park SJ, Yu MA, Kwon HI, Eo S, Kim TS, Seok J, Choi WS, Jeong JH, Lee H, Cho Y, Kwon JA, Jeong M, Maslow JN, Kim YE, Jeon H, Kim KK, Shin EC, Song MS, Jung JU, Choi YK, Park SH.

Nat Commun. 2019 Aug 23;10(1):3836. doi: 10.1038/s41467-019-11815-4.

2.

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN.

Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.

PMID:
31351922
3.

Zika Vaccine Development-Current Progress and Challenges for the Future.

Maslow JN.

Trop Med Infect Dis. 2019 Jul 14;4(3). pii: E104. doi: 10.3390/tropicalmed4030104. Review.

4.

Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease.

Maslow JN, Kwon JJ, Mikota SK, Spruill S, Cho Y, Jeong M.

Hum Vaccin Immunother. 2019 Jul 16:1-9. doi: 10.1080/21645515.2019.1633875. [Epub ahead of print]

PMID:
31215838
5.

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.

Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, McMullan T, Jeong M, Roberts CC, Park YK, Boyer J, Broderick KE, Kobinger GP, Bagarazzi M, Weiner DB, Sardesai NY, White SM.

J Infect Dis. 2019 Jul 2;220(3):400-410. doi: 10.1093/infdis/jiz132.

PMID:
30891607
6.

Course of the Femoral Artery in the Mid- and Distal Thigh and Implications for Medial Approaches to the Distal Femur: A CT Angiography Study.

Maslow JI, Collinge CA.

J Am Acad Orthop Surg. 2019 Jul 15;27(14):e659-e663. doi: 10.5435/JAAOS-D-17-00700.

PMID:
30407980
7.

GeneOne Life Science.

Maslow J.

Hum Vaccin Immunother. 2018;14(11):2548-2549. doi: 10.1080/21645515.2018.1507374. Epub 2018 Oct 26. No abstract available.

8.

The cost and challenge of vaccine development for emerging and emergent infectious diseases.

Maslow JN.

Lancet Glob Health. 2018 Dec;6(12):e1266-e1267. doi: 10.1016/S2214-109X(18)30418-2. Epub 2018 Oct 18. No abstract available.

9.

Assay Challenges for Emerging Infectious Diseases: The Zika Experience.

Roberts CC, Maslow JN.

Vaccines (Basel). 2018 Oct 2;6(4). pii: E70. doi: 10.3390/vaccines6040070. Review.

10.

Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization.

de La Vega MA, Piret J, Griffin BD, Rhéaume C, Venable MC, Carbonneau J, Couture C, das Neves Almeida R, Tremblay RR, Magalhães KG, Park YK, Roberts CC, Maslow JN, Sardesai NY, Kim JJ, Muthumani K, Weiner DB, Kobinger GP, Boivin G.

J Infect Dis. 2019 Jan 9;219(3):365-374. doi: 10.1093/infdis/jiy336.

PMID:
30053014
11.

Prevalence and Clinical Manifestations of the Anconeus Epitrochlearis and Cubital Tunnel Syndrome.

Maslow JI, Johnson DJ, Block JJ, Lee DH, Desai MJ.

Hand (N Y). 2018 Jul 1:1558944718789412. doi: 10.1177/1558944718789412. [Epub ahead of print]

PMID:
30027762
12.

Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.

Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M, Maslow JN, Reed CC, White S, Kim JJ, Kobinger GP, Tebas P, Weiner DB, Muthumani K.

Microbes Infect. 2018 Dec;20(11-12):676-684. doi: 10.1016/j.micinf.2018.03.001. Epub 2018 Mar 17. Review.

13.

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.

Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, Jiang J, Lee B, Ramos S, Broderick KE, Reed CC, Khan AS, Humeau L, Ugen KE, Park YK, Maslow JN, Sardesai NY, Joseph Kim J, Kobinger GP, Weiner DB.

NPJ Vaccines. 2016 Nov 10;1:16021. doi: 10.1038/npjvaccines.2016.21. eCollection 2016.

14.

Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.

Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, Spruill SE, Bagarazzi M, Kobinger GP, Weiner DB, Maslow JN.

N Engl J Med. 2017 Oct 4. doi: 10.1056/NEJMoa1708120. [Epub ahead of print]

15.

Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.

Maslow JN.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28. Review.

16.

Risks to the Superior Gluteal Neurovascular Bundle During Iliosacral and Transsacral Screw Fixation: A Computed Tomogram Arteriography Study.

Maslow J, Collinge CA.

J Orthop Trauma. 2017 Dec;31(12):640-643. doi: 10.1097/BOT.0000000000000996.

PMID:
28787325
17.

DNA vaccination protects mice against Zika virus-induced damage to the testes.

Griffin BD, Muthumani K, Warner BM, Majer A, Hagan M, Audet J, Stein DR, Ranadheera C, Racine T, De La Vega MA, Piret J, Kucas S, Tran KN, Frost KL, De Graff C, Soule G, Scharikow L, Scott J, McTavish G, Smid V, Park YK, Maslow JN, Sardesai NY, Kim JJ, Yao XJ, Bello A, Lindsay R, Boivin G, Booth SA, Kobasa D, Embury-Hyatt C, Safronetz D, Weiner DB, Kobinger GP.

Nat Commun. 2017 Jun 7;8:15743. doi: 10.1038/ncomms15743.

18.

Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection.

Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, Park YK, Weiner DB, Son WC, Maslow JN.

Sci Rep. 2017 Mar 7;7:43531. doi: 10.1038/srep43531.

19.

Vaccine development for emerging virulent infectious diseases.

Maslow JN.

Vaccine. 2017 Oct 4;35(41):5437-5443. doi: 10.1016/j.vaccine.2017.02.015. Epub 2017 Feb 16.

PMID:
28216184
20.

Epidemiology and characteristics of Escherichia coli sequence type 131 (ST131) from long-term care facility residents colonized intestinally with fluoroquinolone-resistant Escherichia coli.

Han JH, Garrigan C, Johnston B, Nachamkin I, Clabots C, Bilker WB, Santana E, Tolomeo P, Maslow J, Myers J, Carson L, Lautenbach E, Johnson JR; CDC Prevention Epicenters Program.

Diagn Microbiol Infect Dis. 2017 Mar;87(3):275-280. doi: 10.1016/j.diagmicrobio.2016.11.016. Epub 2016 Nov 28.

21.

Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia.

Johnson LS, Patel D, King EA, Maslow JN.

Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1151-7. doi: 10.1007/s10096-016-2645-5. Epub 2016 Apr 29.

PMID:
27130036
22.

Etiology of Readmissions Following Orthopaedic Procedures and Medical Admissions. A Comparative Analysis.

Maslow J, Hutzler L, Slover J, Bosco J 3rd.

Bull Hosp Jt Dis (2013). 2015 Dec;73(4):269-75.

23.

Tuberculosis in elephants-a reemergent disease: diagnostic dilemmas, the natural history of infection, and new immunological tools.

Maslow JN, Mikota SK.

Vet Pathol. 2015 May;52(3):437-40. doi: 10.1177/0300985814568357. Epub 2015 Jan 29.

PMID:
25633896
24.

Effectiveness and acceptance of a health care-based mandatory vaccination program.

Leibu R, Maslow J.

J Occup Environ Med. 2015 Jan;57(1):58-61. doi: 10.1097/JOM.0000000000000294.

PMID:
25563540
25.

Patient experience with mupirocin or povidone-iodine nasal decolonization.

Maslow J, Hutzler L, Cuff G, Rosenberg A, Phillips M, Bosco J.

Orthopedics. 2014 Jun;37(6):e576-81. doi: 10.3928/01477447-20140528-59.

PMID:
24972440
26.

Total knee arthroplasty in patients with a previous patellectomy.

Maslow J, Zuckerman JD, Immerman I.

Bull Hosp Jt Dis (2013). 2013;71(3):227-30. Review.

27.

Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities.

Han JH, Maslow J, Han X, Xie SX, Tolomeo P, Santana E, Carson L, Lautenbach E.

J Infect Dis. 2014 Feb 1;209(3):420-5. doi: 10.1093/infdis/jit471. Epub 2013 Aug 28.

28.

Isoniazid Toxicity among an Older Veteran Population: A Retrospective Cohort Study.

Vinnard C, Gopal A, Linkin DR, Maslow J.

Tuberc Res Treat. 2013;2013:549473. doi: 10.1155/2013/549473. Epub 2013 Jan 10.

29.

The international threat of antimicrobial resistance: the perils of paradise.

Maslow JN.

Infect Control Hosp Epidemiol. 2013 Feb;34(2):125-6. doi: 10.1086/669079. Epub 2012 Dec 19. No abstract available.

PMID:
23295557
30.

Mycobacterium avium serovars 2 and 8 infections elicit unique activation of the host macrophage immune responses.

Cebula BR, Rocco JM, Maslow JN, Irani VR.

Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3407-12. doi: 10.1007/s10096-012-1709-4. Epub 2012 Sep 19.

PMID:
22991047
31.

Colonization with extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in long-term care facility residents.

Lautenbach E, Han J, Santana E, Tolomeo P, Bilker WB, Maslow J.

Infect Control Hosp Epidemiol. 2012 Mar;33(3):302-4. doi: 10.1086/664055. Epub 2012 Jan 6.

32.

Genitourinary and pulmonary multidrug resistant Mycobacterium tuberculosis infection in an Asian elephant (Elephas maximus).

Dumonceaux GA, St Leger J, Olsen JH, Burton MS, Ashkin D, Maslow JN.

J Zoo Wildl Med. 2011 Dec;42(4):709-12.

PMID:
22204067
33.

Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007.

Johnson JR, Menard ME, Lauderdale TL, Kosmidis C, Gordon D, Collignon P, Maslow JN, Andrasević AT, Kuskowski MA; Trans-Global Initiative for Antimicrobial Resistance Analysis Investigators.

Emerg Infect Dis. 2011 Nov;17(11):2001-9. doi: 10.3201/eid1711.110488.

PMID:
22099087
34.

Tuberculosis at the human-animal interface: an emerging disease of elephants.

Mikota SK, Maslow JN.

Tuberculosis (Edinb). 2011 May;91(3):208-11. doi: 10.1016/j.tube.2011.02.007. Epub 2011 Mar 11. Review.

PMID:
21397564
35.

Risk factors for fecal colonization with multiple distinct strains of Escherichia coli among long-term care facility residents.

Lautenbach E, Tolomeo P, Black N, Maslow JN.

Infect Control Hosp Epidemiol. 2009 May;30(5):491-3. doi: 10.1086/597234.

36.

Assessment of the use of urine samples to detect colonization with fluoroquinolone-susceptible and fluoroquinolone-resistant Escherichia coli.

Lautenbach E, Babson A, Santana E, Tolomeo P, Black N, Smith CA, Maslow J.

Infect Control Hosp Epidemiol. 2009 Apr;30(4):396-7. doi: 10.1086/596044. No abstract available.

37.

Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens.

Lautenbach E, Bilker WB, Tolomeo P, Maslow JN.

J Clin Microbiol. 2008 Sep;46(9):3094-6. doi: 10.1128/JCM.00945-08. Epub 2008 Jul 23.

38.

Efficient recovery of fluoroquinolone-susceptible and fluoroquinolone-resistant Escherichia coli strains from frozen samples.

Lautenbach E, Santana E, Lee A, Tolomeo P, Black N, Babson A, Perencevich EN, Harris AD, Smith CA, Maslow J.

Infect Control Hosp Epidemiol. 2008 Apr;29(4):367-9. doi: 10.1086/529590.

39.

Bacterial characteristics as predictors of posttherapy recurrent bacteriuria among children with acute uncomplicated cystitis caused by Escherichia coli.

Johnson JR, Johnston B, Murray A, Kuskowski MA, Maslow JN, Johnson C.

Pediatr Infect Dis J. 2007 Dec;26(12):1151-3.

PMID:
18043456
40.

Tuberculosis and multidrug resistance in Zambian prisons, 2000-2001.

Habeenzu C, Mitarai S, Lubasi D, Mudenda V, Kantenga T, Mwansa J, Maslow JN.

Int J Tuberc Lung Dis. 2007 Nov;11(11):1216-20.

PMID:
17958984
41.

Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.

Peloquin CA, Maslow JN, Mikota SK, Forrest A, Dunker F, Isaza R, Peddie LR, Peddie J, Zhu M.

J Vet Pharmacol Ther. 2006 Dec;29(6):581-5. No abstract available.

PMID:
17083464
42.

Population pharmacokinetics of pyrazinamide in elephants.

Zhu M, Maslow JN, Mikota SK, Isaza R, Dunker F, Riddle H, Peloquin CA.

J Vet Pharmacol Ther. 2005 Oct;28(5):403-9.

PMID:
16207301
43.

Fluoroquinolone-resistant Escherichia coli carriage in long-term care facility.

Maslow JN, Lee B, Lautenbach E.

Emerg Infect Dis. 2005 Jun;11(6):889-94.

44.

Pharmacokinetics of ethambutol (EMB) in elephants.

Maslow JN, Mikota SK, Zhu M, Riddle H, Peloquin CA.

J Vet Pharmacol Ther. 2005 Jun;28(3):321-3. No abstract available.

PMID:
15953208
46.

Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).

Maslow JN, Mikota SK, Zhu M, Isaza R, Peddie LR, Dunker F, Peddie J, Riddle H, Peloquin CA.

J Vet Pharmacol Ther. 2005 Feb;28(1):21-7.

PMID:
15720511
47.

Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital.

Maslow JN, Glaze T, Adams P, Lataillade M.

Infect Control Hosp Epidemiol. 2005 Jan;26(1):69-75.

PMID:
15693411
48.

Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.

Viray M, Linkin D, Maslow JN, Stieritz DD, Carson LS, Bilker WB, Lautenbach E.

Infect Control Hosp Epidemiol. 2005 Jan;26(1):56-62.

PMID:
15693409
49.

Utilization of a ts-sacB selection system for the generation of a Mycobacterium avium serovar-8 specific glycopeptidolipid allelic exchange mutant.

Irani VR, Lee SH, Eckstein TM, Inamine JM, Belisle JT, Maslow JN.

Ann Clin Microbiol Antimicrob. 2004 Sep 30;3:18.

50.

Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance.

Maslow JN, Lautenbach E, Glaze T, Bilker W, Johnson JR.

Antimicrob Agents Chemother. 2004 Sep;48(9):3618-20.

Supplemental Content

Loading ...
Support Center